END STAGE RENAL DISEASE PROSPECTIVE PAYMENT SYSTEM

Ardelyx sues US health department over kidney disease drug

The lawsuit claims that CMS's plan to include the drug, Xphozah, along with all other oral-only phosphate lowering therapies in the End-Stage Renal Disease Prospective Payment System (ESRD) will "significantly and negatively impact patient choice of and timely access to important medications."